Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
Screening people with a family history of a multiple myeloma precursor would significantly reduce the chance that a person would develop and die of the cancer, a study reports. Scientists call ... Read more
The European Commission has extended Xgeva‘s (denosumab) approval for the prevention of bone lesions in multiple myeloma patients, Amgen, the medicine’s maker, announced. The injectable therapy, which already was approved for ... Read more
The combination of Revlimid (lenalidomide) and dexamethasone for the treatment of relapsed or refractory multiple myeloma showed similar benefits in routine clinical practice as it did in the clinical trials ... Read more
Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies to treat patients with multiple myeloma ... Read more
Patients with relapsed and refractory multiple myeloma lived roughly 3.6 months longer without their disease worsening when they received a once-weekly dose of Amgen’s Kyprolis (carfilzomib) compared to a twice-weekly dose, ... Read more
Adding Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone has shown promising effectiveness and an acceptable safety profile in multiple myeloma patients who progressed during or after at least one ... Read more
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study. But although the study ... Read more